Buyout target Medivation says cancer drug could be "best in class"

July 6 (Reuters) - Medivation Inc, which has opened its books to potential buyers, on Wednesday said its experimental cancer drug talazoparib is likely the best in a new class known as PARP inhibitors and pivotal trial data could be reported earlier than planned.